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BACKGROUND: The National Health Service (NHS) bowel cancer screening programme (BCSP) was initiated across England in April
2006. To determine the feasibility of using national cancer registration data to assess the impact of the BCSP on stage-specific
incidence, we studied trends in the incidence rates of colon (ICD10 C18) and rectosigmoid junction and rectum (ICD10 C19–C20)
cancers and the completeness of data on Dukes stage in England.
METHODS: Data were obtained from all nine cancer registries for the period 1996–2004, before the introduction of the BCSP, in men
and women aged 50–79 years.
RESULTS: Overall, incidence rates declined by 1% per year in the 9 years before the introduction of the BCSP (Po0.001). Dukes stage
was recorded for 60% of all registrations but this varied between regions and over time. Only four registries had completeness of
74% or more. Registrations with unknown Dukes stage decreased from 1996 to 2000, and then increased during 2001–2004
affecting trends in stage-specific incidence.
CONCLUSION: To study the impact of the BCSP on stage-specific incidence, regional variations in data completeness need to be
addressed.
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Screening by fecal occult blood testing (FOBt) has been shown
to significantly reduce mortality from bowel cancer in randomised
controlled trials. A trial in Nottingham, UK, showed a 15%
reduction in bowel cancer mortality in those randomised to the
intervention arm and offered biennial FOBt screening at a median
of 7.8 years follow-up (Hardcastle et al, 1996). In 2000, a pilot
study (UK Colorectal Cancer Screening Pilot Group, 2004; Weller
et al, 2007) was established to assess the feasibility of population-
based screening for bowel cancer in the United Kingdom using
FOBt. The results of the pilot supported roll out of the National
Health Service (NHS) bowel cancer screening programme (BCSP),
which was initiated across England in April 2006 (NHS Bowel
Cancer Screening Programme, 2008). It is anticipated that full
coverage will be achieved by the end of 2009. A total of five million
men and women aged 60–69 years will be offered screening by
FOBt every 2 years. An extension of the age range up to 75 years is
planned from April 2010.
The main aim of the screening programme is to reduce bowel
cancer mortality by detecting bowel cancers in asymptomatic
people at an early stage when treatment is most effective. Screening
also detects adenomas, which could potentially develop into
cancers, and removal of these will reduce the risk of developing
bowel cancer in affected individuals. The expected reduction in
bowel cancer mortality is unlikely to be observable for many years,
and it is therefore important to study interim measures of
performance to assess whether the screening programme is on
track to achieve the expected benefit. Monitoring interim
performance measures will also ensure that the information being
collected is appropriate, adequate and of high quality.
Survival of bowel cancer patients decreases markedly with
increasingly advanced stage of disease. Dukes classification
(Dukes, 1949) is widely used to describe the staging of bowel
cancer; a change in the distribution of Dukes stage is therefore a
key performance indicator. A reduction in the incidence rate of
late stage (Dukes C & D) cancers would be expected to precede a
reduction in bowel cancer mortality because of screening. Studies
of the local impact of the bowel cancer Pilot in Coventry and north
Warwickshire (Goodyear et al, 2008) found a significantly lower
proportion of advanced cancers in those detected by screening
compared with those not screen detected.
A previous assessment of bowel cancer registration data for
the Oxford region (Green et al, 2007) concluded that incomplete
registry data and changing recording practices may affect future
evaluation of bowel cancer screening.
The aim of this paper is to report the trends nationwide in cancers
of the colon (ICD10 C18) and of the rectosigmoid junction and
rectum (ICD10 C19 and C20) for England for the period 1996–2004
before the introduction of the national screening programme, and to
assess the completeness and quality of data from all registries.
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sMATERIALS AND METHODS
Individual data on colorectal cancer registrations for men and
women aged 50–79 years over the period 1996–2004, were
collected from the nine English cancer registries existing during
this period: Eastern Cancer Registration and Information Centre
(ECRIC), Merseyside and Cheshire Cancer Registry (MCCR),
North Western Cancer Registry (NWCR), Northern and Yorkshire
Cancer Registry and Information Service (NYCRIS), Oxford
Cancer Intelligence Unit (OCIU), South West Cancer Intelligence
Service (SWCIS), Thames Cancer Registry (Thames), Trent Cancer
Registry (Trent) and West Midlands Cancer Intelligence Unit
(WMCIU). The National Minimum Dataset(United Kingdom
Association of Cancer Registries, 2008) for colorectal cancer
registrations includes: patient unit number, NHS number, name,
postcode, sex, date of birth, date of diagnosis, site of primary
neoplasm, morphology, Dukes stage and grade of tumour. These
data were collated by NYCRIS and anonymised before being sent
to the Cancer Screening Evaluation Unit.
A number of additional variables derived by NYCRIS were
included in the extract supplied. These were tumour identification
code, number of tumours, postal district, and a variable indicating
whether the tumour was registered in two registries. In addition a
composite Dukes stage was generated. Cancer registries record up
to three types of stage for colorectal tumours: Dukes, pathological
TNM and clinical TNM. These three different staging systems have
been combined so that just Dukes stage is reported. To do this the
following rules were applied. Firstly, all pathological and clinical
TNM stages were converted to a Dukes stage and pathological
TNM or Dukes were taken as the ‘gold standard’ staging
information. However, if both a pathological TNM and a Dukes
stage had been reported, but they did not agree the highest stage
available was used. In addition if no pathological TNM or Dukes
was available but a clinical TNM stage was available, then clinical
stage was used. Finally if no Dukes, pathological TNM or clinical
TNM was available then the tumour was classed as unstaged.
Duplicate registrations can occur when diagnosis takes place
in one registry but treatment occurs in another, either because
an individual has moved between diagnosis and treatment or
because they were treated in a hospital in a different region. Before
analysis, any duplicate registrations that could be identified and
that were not true multiple primaries were removed.
Crude age- and sex-specific bowel cancer incidence rates per
100000 persons were calculated in 5-year age groups for the whole of
England, by cancer site and by Dukes stage. The national population
counts for the denominators were obtained in 5-year age and sex
subgroups for the years 1996–2004 from the Office for National
Statistics. Crude age- and sex-specific bowel cancer incidence rates
per 100000 were also calculated for populations covered by cancer
registries. Cancer registry population counts used in the denomi-
nator were provided in 5-year age and sex subgroups for the years
1996–2004 by UKACR (United Kingdom Association of Cancer
Registries, 2009). These population counts of 50 to 79 year olds for
each year were estimated for the eight cancer registries as they exist
in 2009 by their geographical catchment area: ECRIC, the merged
MCCR and NWCR called the North West Cancer Intelligence Service
(NWCIS), NYCRIS, OCIU, SWCIS, Thames, Trent and WMCIU. The
crude sex-specific incidence rates were adjusted for age using the
European population as standard (Doll and Cook, 1967). Poisson
regression modelling was used to investigate how incidence rates
differ by age, sex, year of registration and cancer registry using the
STATA (version 9.2) statistical package.
Completeness of Dukes stage was measured as the proportion of
all registered cases, which were categorised as known stage (A–D).
Tumour grade completeness was measured as the proportion
of cases categorised as known grade (well, moderate, poor or
undifferentiated). Completeness of TNM stage was not studied
separately. It was not part of the National Minimum Dataset
(United Kingdom Association of Cancer Registries, 2008) over the
period of study and there was insufficient information to permit
valid analysis either by registry or nationally.
The 2004 national peer review of cancer registry measures
(Department of Health, 2005) recommended that registries should
have Dukes stage information for a minimum of 74% of bowel
cancer cases. In line with these recommendations, stage-specific
incidence rates were first calculated using the full dataset and then
restricted to cancer registries, which had a minimum of 74%
completeness for the period 1996–2004. Incidence rates by stage
are reported here from the restricted dataset only.
RESULTS
Between 1996 and 2004, a total of 177379 individual bowel cancers
in men and women aged 50–79 years were registered in England.
There were 109196 cancers of the colon and 68183 cancers of the
rectosigmoid junction and rectum. Crude incidence rates for all
sites (ICD10 C18–C20) for men and women were 172 per 100000
and 117 per 100000 in 1996, and 163 per 100000 and 105 per
100000 in 2004, respectively.
Table 1 shows that the mean age at diagnosis was slightly, but
significantly, lower in men (68.4 years) than in women (69.0 years)
(Po0.001) Age-specific incidence rate ratios of men/women shows
that the rate was higher in men than women in each age group,
for example, in 2004 for age groups 50–54, 55–59, 60–64, 65–69,
70–74 and 75–79 years the ratios were 1.38, 1.46, 1.68, 1.64, 1.71
and 1.69, respectively. Mean age at diagnosis for cancers of the
rectosigmoid junction and rectum was significantly younger than
for cancers of the colon (68.0 years compared with 69.1,
respectively) (Po0.001).
Age-standardised incidence rates of bowel cancer declined
between 1996 and 2004 (Figure 1). The results of a Poisson
regression analysis showed that after adjustment for age and
cancer registry, incidence rates declined by an average of 1%
(Po0.001) each year for both men and women; when sex was
included in the model, the risk of bowel cancer was 39% lower for
women compared with men (Po0.001).
Age and sex-specific incidence rates also declined significantly
(Po0.001) by 1% each year for all age–sex groups except for the
75–79 year olds in which there was no change in women and a
slight increase in men (Figure 2). Both incidence rates and their
decrease with time varied between cancer registries.
Age-standardised incidence rates of bowel cancer for the study
period as a whole varied considerably between cancer registries for
men, but less so for women. Incidence rates in men varied from
111 per 100000 in the Thames Cancer Registry region to 140 per
100000 in the NYCRIS region. In women, incidence rates varied
from 70 per 100000 in the Trent Cancer registry region to 83 per
100000 in OCIU region. Men in the ECRIC region and women in
the WMCIU region experienced the largest drops in rates between
1996 and 2004 of 16 and 17 per 100000, respectively. In contrast,
incidence rates for both men and women in the SWCIS and Trent
Cancer registry regions increased slightly (between 0.4 and 1.4 per
100000) but these changes were not significant (P40.05).
Site-specific incidence
Age-standardised incidence rates of colon cancer (ICD10 C18)
were higher than those for cancers of the rectosigmoid junction
and rectum (ICD10 C19 and C20) (Figure 1) and declined steadily
between 1996 and 2004. Poisson regression analysis showed that
after adjusting for age, sex and cancer registry, incidence rates for
colon cancer were higher than those for rectosigmoid junction and
rectum cancers (Po0.001) (35% higher in men and 106% higher in
women). There was a 1% yearly decline in incidence rates in colon
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scancers in both sexes and for rectosigmoid junction and rectum
cancers in women (Po0.001).
Dukes stage and grade
Using the composite Dukes stage described in the Materials and
Methods section, Dukes stage was recorded for 60% of all
registrations (Table 2). Completeness was slightly higher for colon
cancers compared with those of the rectosigmoid junction and rectum
(62 and 58%, respectively). Completeness of stage did not vary by
gender but it was lower in those aged 75–79 years compared with the
50–54 year olds (60 vs 63%, respectively for colon cancers and 54 vs
61% for the rectosigmoid junction and rectum). Completeness varied
between cancer registries; ECRIC, NYCRIS, OCIU and WMCIU had
the highest levels (X74%, Table 2). Completeness in all but one
registry improved over time between 1996 and 2000.
Figure 3 displays the age-standardised incidence rates, by Dukes
stage, after restricting the data to those four cancer registries with
stage completeness of 74% or above. Incidence rates for all known
stages, but less so for Dukes stage B, increased during the period
1996 to 2001, for both men and women, and were highest for
Dukes stage C&D. However, from 2001 the rates declined.
Incidence rates of unknown Dukes stage declined significantly
(Po0.001) over the period 1996–2001 and this is likely to account
for most of the increase in rates for known stages during this
period. After 2001, the rate of unknown stage cancers increased,
coinciding with the decline in the rate of cancers with known stage.
Tumour grade was recorded for 54% of all registrations, but
reliable and complete grades were recorded for only 46% of all
registrations.
DISCUSSION
We have analysed bowel cancer incidence rates and completeness
of stage data from all cancer registries in England for the period
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Figure 1 European age-standardised incidence rates of bowel cancer
(ICD10 C18–C20), by sex, and by sex and site in 50–79 year olds: England
1996–2004.
Table 1 Malignant neoplasms of the colon (ICD10 C18) and of the rectosigmoid junction and rectum (ICD10 C19–C20): England 1996–2004
Cancer site
ICD10 C18 ICD10 C19–C20
Total Male patients Female patients Total Male patients Female patients
Number of registrations 109196 59197 49999 68183 43905 24278
Mean age at diagnosis (years) 69.1 68.9 69.3 68.0 67.8 68.4
Dukes stage
A 6509 (6%) 3605 (6%) 2904 (6%) 8107 (12%) 5069 (12%) 3038 (13%)
B 26873 (25%) 14264 (24%) 12609 (25%) 12401 (18%) 8176 (19%) 4225 (17%)
C 25283 (23%) 13597 (23%) 11686 (23%) 14848 (22%) 9434 (21%) 5414 (22%)
D 8610 (8%) 4800 (8%) 3810 (8%) 4373 (6%) 2972 (7%) 1401 (6%)
Unknown 41921 (38%) 22931 (39%) 18990 (38%) 28454 (42%) 18254 (42%) 10200 (42%)
Grade
Well differentiated 5879 (5%) 3327 (6%) 2552 (5%) 3556 (5%) 2310 (5%) 1246 (5%)
Moderately differentiated 43371 (40%) 24240 (41%) 19131 (38%) 30449 (45%) 19981 (46%) 10468 (43%)
Poorly differentiated 8049 (7%) 4011 (7%) 4038 (8%) 4446 (7%) 2887 (7%) 1559 (6%)
Undifferentiated 144 o1% 71 o1% 73 o1% 70 o1% 43 o1% 27 (o1%)
Unknown 51753 (47%) 27548 (47%) 24205 (48%) 29662 (44%) 18684 (43%) 10978 (45%)
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Figure 2 Age-specific incidence rates of bowel cancer (ICD10 C18–
C20), by sex: England 1996–2004.
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sbefore the introduction of the national screening programme. The
underlying trend in bowel cancer incidence rates in England, for
both men and women, showed a steady and significant decline
over the 9-year period before the introduction of the screening
programme, averaging around 1% per year. Colon cancers
accounted for 62% of all registrations (57% for men and 67% for
women). Between 1996 and 2004, incidence rates declined across
all cancer sites and all age groups excluding the oldest age group
and rectal cancers in men.
A significant finding was the incompleteness of data on stage,
with overall 40% of registrations having no Dukes stage
information. Regional variation in completeness partly reflects
differing recording practices and the extent to which registries are
able to verify metastatic disease and avoid recording the Dukes
stage as ‘unknown’. Of particular concern was the change over
time in the rate of cancers with stage unknown, as such changes
will affect the rate of cancers of known stage. In the period studied,
the rate of cancers with stage unknown decreased until 2001 and
then showed a slight increase until 2004. As noted elsewhere poor
levels of completeness will hamper future analyses of stage
registration within the screening programme framework (Green
et al, 2007). One solution would be to restrict analyses to data from
registries, which have at least 74% completeness in line with the
2004 National Cancer Peer Review Standards (Department of
Health, 2005). The recent increase in cancers with stage unknown
will be partly due to increasing use of neo-adjuvant treatments in
the management of rectal tumours, and the lead registry for
colorectal cancer NYCRIS (in collaboration with the UKACR) has
recommended that registries should switch from collecting Dukes
stage to TNM (Version 5) and that registry data systems should
incorporate a y prefix to TNM stages to indicate those patients
who underwent neo-adjuvant treatment. This level of detail would
enhance the data quality and future analysis.
A strength of this paper is that it presents results for all registries
in England. A limitation of our analysis is that cancer registry
population counts were only available based on 2009 registry
boundaries. In the years following the end of our study period
there were a number of changes to registry catchment areas, but we
were only able to calculate registry incidence rates for registries
based on the 2009 boundaries. However, aggregated cancer registry
population counts, by year, closely match the national counts.
This paper has not investigated ascertainment levels of bowel
cancer registrations between registries. However, the trends in
incidence rates indicate that it is unlikely that there were variations
in case ascertainment over time.
Monitoring the performance and success of the screening
programme will be an ongoing exercise. There are five screening
hubs in England, each responsible for co-ordinating the screening
programme in around 20 local screening centres (NHS Bowel
Table 2 Dukes stage completeness for bowel cancer by cancer registry in England 1996–2004, and population size in 2004 for male and female patients
combined aged 50–79 years
Cancer registry
National
Year of
diagnosis
East
Anglian
Merseyside and
Cheshire
North
West
Northern and
Yorkshire Oxford
South
West Thames Trent
West
Midlands
Total
(%)
Total
count
1996 93 3 0 42 79 31 57 10 70 43 19404
1997 94 39 0 64 84 44 56 12 70 51 19356
1998 92 52 0 88 83 58 60 18 74 59 20309
1999 93 35 0 88 85 58 62 52 75 62 20217
2000 93 65 0 92 85 61 63 59 76 65 20382
2001 93 63 0 93 82 71 62 80 76 69 19455
2002 94 59 0 91 85 71 60 74 74 68 19292
2003 95 69 0 89 82 76 59 57 72 66 19328
2004 94 62 0 87 81 81 57 8 75 61 19636
Total % 93 49 0 82 83 61 60 41 74 60
Total count 10465 9428 15602 26287 8780 27882 41644 17395 19896 177379
Population size
a 1675755 1937893
b 2010468 762758 2174144 2972706 1482587 1591663 14607974
aUsing boundaries for the eight cancer registries as they exist in 2009.
bRegistries Merseyside and Cheshire, and North West were combined to form the North West Cancer
Intelligence Service (NWCIS).
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Figure 3 European age-standardised incidence rates of bowel cancer
(ICD10 C18–C20) in Eastern, Northern and Yorkshire, Oxford and
West Midlands cancer registries by Dukes stage and sex: England
1996–2004.
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sCancer Screening Programme, 2008). The BCSP has been rolled out
gradually by PCT and it may be possible to study future incidence
according to the timing of the introduction of screening. Full
coverage is due to be achieved by December 2009. Over the study
period there were 257395 bowel cancers in all ages in our dataset,
of these 23% were in the screening age range (60–69 years).
The full effect of the programme on mortality from bowel cancer
is not likely to emerge until around 2020. However, it has recently
been demonstrated that the benefit of flexible sigmoidoscopy
screening on bowel cancer mortality could be estimated by
predicting colorectal cancer mortality based on stage-specific
incidence thus reducing the required follow-up time by around 3
years (Cuzick et al, 2007). The approach requires reliable stage
data and it was emphasised that the routine collection of such data
should be a priority for cancer registries.
The screening programme should also lead to the detection and
removal of adenomas before they develop into cancers, which in
turn could lead to an overall reduction in the underlying bowel
cancer incidence rate. However, there is no indication so far from
the Nottingham RCT, whose protocol the screening programme
follows, that such a reduction will be observed (Scholefield et al,
2002) and any reduction is likely to take around 15–20 years.
National FOBt screening programmes have been implemented in
several countries, either in full or part (Benson et al, 2008), but most
are recent developments, and few results about the effect on
incidence have been published. In Japan, where the screening
programme commenced in 1993, an increase in age-standardised
incidence rates of screen detected bowel cancer was observed in the
first 4 years; compared with 1988–1992, incidence increased 1.4 and
1.2 times for men and women, respectively (Minami et al, 2006).
Changes in age-specific bowel cancer incidence will provide an
early indication of the effect of the programme, although they
will not provide evidence of an eventual impact on mortality.
In the first few years after the introduction of the programme,
the incidence rate would be expected to increase because of the
detection of prevalent cases by screening. The incidence rate would
then be expected to return almost to the background level, except
in the youngest age group offered screening in which prevalent
screens will still be taking place (Quinn et al, 1995). There should
also be a slight fall in incidence in the age group just above the
screening age range due to earlier diagnosis of cancers that would
otherwise have occurred at these ages.
In conclusion, analyses of stage-specific incidence rates before
the introduction of the BSCP will need to take into account Dukes
stage completeness. The effect of earlier diagnosis because of
programme awareness and changes in registration practices should
also be considered.
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